MBB Public Markets’s Kyverna Therapeutics KYTX Stock Holding History

MBB Public Markets’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.3M	Hold	614,477	–	–	0.63%	11
2025 Q4	$5.78M	Hold	614,477	–	–	0.6%	14
2025 Q3	$3.69M	Hold	614,477	–	–	0.49%	16
2025 Q2	$1.89M	Hold	614,477	–	–	0.18%	27
2025 Q1	$1.19M	Hold	614,477	–	–	0.13%	34
2024 Q4	$2.3M	Hold	614,477	–	–	0.21%	54
2024 Q3	$3M	Buy	614,477 +204,286	+50%	+$1.57M	0.17%	70
2024 Q2	$3.08M	Buy	+410,191	New	+$6.27M	0.06%	248

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

MBB Public Markets's KYTX Position: Q1 2026 in Review

MBB Public Markets held its Kyverna Therapeutics (KYTX) position steady in Q1 2026 at 614,477 shares worth $5.3M. The position accounts for 0.63% of the portfolio, ranked #11.

MBB Public Markets first reported a position in KYTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $5.78M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

MBB Public Markets held 614,477 shares of Kyverna Therapeutics worth $5.3M as of Q1 2026.
MBB Public Markets left its Kyverna Therapeutics share count unchanged in Q1 2026.
Kyverna Therapeutics made up 0.63% of MBB Public Markets's portfolio in Q1 2026, its #11 holding.
MBB Public Markets first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 8 quarters since.
MBB Public Markets's Kyverna Therapeutics position peaked at $5.78M in Q4 2025.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on MBB Public Markets's 13F filing for Q1 2026, filed 15 May 2026.